A comparative pharmacokinetic and pharmacodynamic study of two novel Cuban PEGylated rHuEPO versus MIRCERA® and ior®EPOCIM
Context: The recombinant human erythropoietin (rHuEPO) stimulates the erythropoiesis process. Because this glycoprotein has a short half-life, it needs to be administrated two to three times a week. One of the technics to solve this issue is the PEGgilation. Aims: To evaluate the pharmacokinetics (P...
Saved in:
Main Authors: | Gledys Reynaldo (Author), Leyanis Rodríguez (Author), Roberto Menéndez (Author), Joaquín Solazábal (Author), Daniel Amaro (Author), María de los A. Becquer (Author), Yamila Colom (Author), Haydee Gil (Author), Juan C. Polo (Author), Gilberto Castañeda (Author), Braulio Jiménez-Vélez (Author), Jorge Duconge (Author), Eduardo M. Fernández-Sánchez (Author) |
---|---|
Format: | Book |
Published: |
GarVal Editorial Ltda.,
2018-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EQUIVALENCIA TERAPEUTICA ENTRE IOR® EPOCIM Y EPO SIN ALBUMINA EN PACIENTES CON INSUFICIENCIA RENAL CRONICA EN HEMODIÁLISIS Therapeutic equivalence between IOR® EPOCIM and EPO without albumin in patients in hemodyalisis with Chronic renal Insufficiency
by: Jorge F. Pérez-Oliva, et al.
Published: (2008) -
Equivalencia terapéutica entre IOR® EPOCIM y EPO sin albúmina en pacientes con insuficiencia renal crónica en hemodiálisis
by: Jorge Pérez-Oliva Díaz, et al.
Published: (2008) -
Comparison between two treatment protocols with recombinant Human Erythropoietin (rHuEpo) in the treatment of late anemia in neonates with Rh-Isoimmunization
by: A.A. Zuppa, et al.
Published: (2012) -
Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment
by: Farooqahmed S. Kittur, et al.
Published: (2023) -
Efectividad y seguridad del uso de ior® EPOCIM en pacientes en prediálisis Ensayo clínico
by: Alicia Vargas Batista, et al.
Published: (2016)